Related Experiment Videos
Essential myoclonus: response to anticholinergic therapy.
Clinical Neuropharmacology
|January 1, 1984
Summary
Benztropine mesylate effectively reduced involuntary jerking movements in patients with essential myoclonus. This study highlights its potential as a treatment for this neurological disorder.
Area of Science:
- Neurology
- Pharmacology
Background:
- Essential myoclonus is characterized by involuntary, brief jerking movements.
- Current treatment options for essential myoclonus can be limited.
Observation:
- Three patients diagnosed with essential myoclonus were observed.
- These patients included a sibling pair and one individual with a sporadic case.
Findings:
- Benztropine mesylate, administered in daily dosages ranging from 4 to 9 mg, demonstrated a significant reduction in myoclonic jerks.
- The medication proved effective in suppressing the involuntary movements across all observed patients.
Implications:
- Benztropine mesylate shows promise as a therapeutic agent for managing essential myoclonus.
- Further research may explore optimal dosing and long-term efficacy of benztropine mesylate in myoclonus treatment.